Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 0.47 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.47 |
| ▸ | MT-CO2 | P00403 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | RIOK2 | Q9BVS4 | 4/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | GSK3A | P49840 | 2/20 | 0.37 |
| ▸ | MAPK10 | P53779 | 2/20 | 0.37 |
| ▸ | KDM1A | O60341 | 1/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.36 |
| ▸ | AR | P10275 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24031006 | 0.84 | KMT2A (0.39) | PTGS1KMT2AHPGDTDP1AR | |
| SCHEMBL30489969 | 0.84 | PTGS1 (0.47) | PTGS1PTGS2MT-CO2KMT2ARIOK2 | |
| SCHEMBL24094531 | 0.84 | PTGS1 (0.47) | PTGS1PTGS2MT-CO2KMT2ARIOK2 | |
| SCHEMBL27845906 | 0.83 | KDM1A (0.37) | PTGS1PTGS2RIOK2GSK3AMAPK10 | |
| SCHEMBL27646025 | 0.82 | MT-CO2 (0.48) | PTGS1PTGS2MT-CO2KMT2ARIOK2 | |
| SCHEMBL29002085 | 0.82 | MT-CO2 (0.48) | PTGS1PTGS2MT-CO2KMT2ARIOK2 | |
| SCHEMBL24031007 | 0.81 | PTGS2 (0.46) | PTGS1PTGS2KMT2AHPGD | |
| SCHEMBL29272210 | 0.81 | PTGS1 (0.47) | PTGS1PTGS2MT-CO2KMT2ARIOK2 | |
| SCHEMBL12076114 | 0.80 | EPHX1 (0.41) | RIOK2GSK3AMAPK10KDM1AHDAC1 | |
| SCHEMBL16797542 | 0.79 | ALDH1A1 (0.48) | PTGS1PTGS2MT-CO2KMT2ARIOK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024020034-A1 | CBL-B INHIBITORS AND METHODS OF USE THEREOF | ARCUS BIOSCIENCES, INC. (US) | 2024-01-25 | — | — | WO | disclosed |
| US-20230219961-A1 | Pyridine acetamide derivative serving as CDK inhibitor, and preparation method therefor and use thereof | Suzhou Alphama Biotechnology Co., Ltd. (CN) | 2023-07-13 | — | — | US | disclosed |
| US-20230219961-A1 | Pyridine acetamide derivative serving as CDK inhibitor, and preparation method therefor and use thereof | Suzhou Alphama Biotechnology Co., Ltd. (CN) | 2023-07-13 | — | — | US | disclosed |
| CN-115340555-A | Pyridine acetamide derivative as CDK inhibitor, and preparation method and application thereof | 苏州阿尔脉生物科技有限公司 | 2022-11-15 | — | — | CN | disclosed |
| CN-113173924-B | Pyridine acetamide derivative as CDK inhibitor, and preparation method and application thereof | 苏州阿尔脉生物科技有限公司 | 2022-07-19 | — | — | CN | disclosed |
| CN-113173924-A | Pyridine acetamide derivative as CDK inhibitor, and preparation method and application thereof | 苏州阿尔脉生物科技有限公司 | 2021-07-27 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219961-A1 | Pyridine acetamide derivative serving as CDK inhibitor, and preparation method therefor and use thereof | CDK9, CDK7, CDK8 | PTGS1 1205/4885PTGS2 2365/4885MT-CO2 3447/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.